

UK

ELOCON SCALP LOTION

ABRIDGED PRESCRIBING INFORMATION

Uses: Elocon Scalp Lotion contains mometasone furoate 0.1% w/w, a synthetic topical corticosteroid. It is indicated for the treatment of inflammatory and pruritic manifestations of psoriasis and seborrhoeic dermatitis of the scalp.

Dosage: A few drops of Elocon Scalp Lotion should be applied to affected scalp sites once daily and gently massaged in.

Contraindications, Precautions etc.: *Contraindications:* Bacterial, viral and fungal infections. Hypersensitivity to mometasone furoate or to other corticosteroids. *Precautions:* Elocon treatment should be discontinued if irritation or sensitisation develop or in the presence of infection not adequately controlled by antifungal or antibacterial therapy. Courses in children should be limited to 5 days. Long term continuous therapy should be avoided in all patients. Use in psoriasis may result in rebound relapse due to tolerance, risk of generalised pustular psoriasis or local systemic toxicity due to impaired barrier function of skin. Careful supervision is important. Care must be taken to keep the preparation away from the eyes. There is inadequate evidence of safety in human pregnancy. Corticosteroids may carry a very small risk of abnormalities in foetal development. Contains propylene glycol which may cause skin irritation.

Side Effects: Local reactions include paresthesia, burning, pruritus, tingling, stinging, application site reactions, bacterial infection, folliculitis, furunculosis, allergic contact dermatitis, hypopigmentation, hypertrichosis, secondary infection, striae, acneiform reactions and signs of skin atrophy.

Paediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced hypothalamic-pituitary-adrenal axis suppression and Cushing's Syndrome. Other less common and rarely reported side effects are listed in the SPC.

Overdosage: Excessive use may result in suppression of pituitary adrenal function and secondary adrenal insufficiency which is usually reversible. Accidental oral ingestion is unlikely to produce harmful effects due to the low steroid content.

Presentation: 30ml bottles. **Basic NHS price:** £4.37 (30ml); **Marketing Authorisation Number:** PL 00025/0579. **Legal Category:** POM.

Marketing Authorisation Holder: Merck Sharp & Dohme Limited, Hertford Road, Hoddesdon, Hertfordshire, EN11 9BU, UK.

Please refer to the full SPC text before prescribing this product. Adverse events should be reported. Reporting forms and information can be found at www.yellowcard.gov.uk. Adverse events should also be reported to MSD Drug Safety Department on +44 (0)1707 363773.

Date of Revision of the text: April 2011

Elocon SL/API/UK/04-11/06